FR15C0078I2 - Modulateurs de proprietes pharmacocinetiques d'agents therapeutiques - Google Patents
Modulateurs de proprietes pharmacocinetiques d'agents therapeutiquesInfo
- Publication number
- FR15C0078I2 FR15C0078I2 FR15C0078C FR15C0078C FR15C0078I2 FR 15C0078 I2 FR15C0078 I2 FR 15C0078I2 FR 15C0078 C FR15C0078 C FR 15C0078C FR 15C0078 C FR15C0078 C FR 15C0078C FR 15C0078 I2 FR15C0078 I2 FR 15C0078I2
- Authority
- FR
- France
- Prior art keywords
- modulators
- therapeutic agents
- pharmacokinetic properties
- pharmacokinetic
- properties
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
- C07C209/78—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton from carbonyl compounds, e.g. from formaldehyde, and amines having amino groups bound to carbon atoms of six-membered aromatic rings, with formation of methylene-diarylamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C315/00—Preparation of sulfones; Preparation of sulfoxides
- C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81931506P | 2006-07-07 | 2006-07-07 | |
US83237106P | 2006-07-21 | 2006-07-21 | |
US90322807P | 2007-02-23 | 2007-02-23 | |
PCT/US2007/015604 WO2008010921A2 (en) | 2006-07-07 | 2007-07-06 | Modulators of pharmacokinetic properties of therapeutics |
Publications (2)
Publication Number | Publication Date |
---|---|
FR15C0078I1 FR15C0078I1 (ja) | 2016-01-08 |
FR15C0078I2 true FR15C0078I2 (fr) | 2016-04-22 |
Family
ID=38729072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR15C0078C Active FR15C0078I2 (fr) | 2006-07-07 | 2015-12-02 | Modulateurs de proprietes pharmacocinetiques d'agents therapeutiques |
Country Status (34)
Country | Link |
---|---|
US (11) | US8067449B2 (ja) |
EP (4) | EP3696171A1 (ja) |
JP (2) | JP4881433B2 (ja) |
KR (3) | KR101477822B1 (ja) |
CN (2) | CN103275033B (ja) |
AP (1) | AP2985A (ja) |
AR (1) | AR061838A1 (ja) |
AU (1) | AU2007275860C1 (ja) |
BR (1) | BRPI0714055B8 (ja) |
CA (1) | CA2653374A1 (ja) |
CY (2) | CY1116688T1 (ja) |
DK (1) | DK2049506T4 (ja) |
EA (2) | EA020489B1 (ja) |
ES (3) | ES2611308T3 (ja) |
FI (1) | FI2049506T4 (ja) |
FR (1) | FR15C0078I2 (ja) |
HK (2) | HK1126485A1 (ja) |
HR (2) | HRP20090077B1 (ja) |
HU (1) | HUE025565T4 (ja) |
IL (2) | IL195488A (ja) |
LT (1) | LTC2049506I2 (ja) |
LU (1) | LU92864I2 (ja) |
ME (1) | ME02258B (ja) |
MX (1) | MX2009000234A (ja) |
NL (1) | NL300780I2 (ja) |
NO (4) | NO343776B1 (ja) |
NZ (1) | NZ573060A (ja) |
PL (1) | PL2049506T3 (ja) |
PT (2) | PT2049506E (ja) |
RS (1) | RS54237B9 (ja) |
SG (1) | SG183007A1 (ja) |
SI (1) | SI2049506T1 (ja) |
TW (2) | TWI411613B (ja) |
WO (1) | WO2008010921A2 (ja) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7786153B2 (en) | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
EP3696171A1 (en) | 2006-07-07 | 2020-08-19 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
EP2465855A1 (en) * | 2006-08-31 | 2012-06-20 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
AU2015204378B2 (en) * | 2007-02-23 | 2017-03-09 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
EP2487168A1 (en) | 2007-02-23 | 2012-08-15 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
HUE029866T2 (en) * | 2007-02-23 | 2017-03-28 | Gilead Sciences Inc | Modulation of pharmacokinetic parameters of therapeutic agents |
AU2013204815B2 (en) * | 2007-02-23 | 2015-05-07 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
JP5547067B2 (ja) * | 2007-06-29 | 2014-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | 治療組成物およびその使用 |
EA200971093A1 (ru) * | 2007-06-29 | 2010-08-30 | Джилид Сайэнс, Инк. | Терапевтические композиции и их применение |
AR067412A1 (es) * | 2007-07-06 | 2009-10-07 | Gilead Sciences Inc | Moduladores de propiedades farmaceuticas de productos terapeuticos |
US20090175824A1 (en) * | 2007-11-20 | 2009-07-09 | Craig Masse | Peptides for the treatment of HCV infections |
PT2231628E (pt) * | 2008-01-04 | 2015-12-29 | Gilead Sciences Inc | Inibidores de citocromo p450 |
ES2572631T3 (es) | 2008-01-25 | 2016-06-01 | Chimerix, Inc. | Métodos de tratamiento de infecciones virales |
US10039718B2 (en) * | 2008-05-02 | 2018-08-07 | Gilead Sciences, Inc. | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
ES2623016T3 (es) | 2008-12-23 | 2017-07-10 | Gilead Pharmasset Llc | Fosforamidatos de nucleósido de 2-amino purina 6-O-sustituida |
NZ593649A (en) | 2008-12-23 | 2013-11-29 | Gilead Pharmasset Llc | Nucleoside analogs |
EA019295B1 (ru) | 2008-12-23 | 2014-02-28 | Джилид Фармассет, Ллс. | Соединения пуриновых нуклеозидов и способ их получения |
EA021313B1 (ru) * | 2009-02-06 | 2015-05-29 | Джилид Сайэнс, Инк. | Таблетки для комбинированной терапии |
UA108738C2 (uk) * | 2009-04-03 | 2015-06-10 | Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки | |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
SI2609923T1 (sl) | 2010-03-31 | 2017-10-30 | Gilead Pharmasset Llc | Postopek za kristalizacijo (s)-izopropil 2-(((s)-(perfluorofenoksi) (fenoksi)fosforil)amino)propanoata |
HUE026235T2 (en) | 2010-03-31 | 2016-06-28 | Gilead Pharmasset Llc | Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate |
EP2418196A1 (en) * | 2010-07-29 | 2012-02-15 | IMTM GmbH | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors |
MY158809A (en) * | 2010-09-22 | 2016-11-15 | Craun Res Sdn Bhd | Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same |
WO2012045007A1 (en) | 2010-10-01 | 2012-04-05 | Gilead Sciences, Inc. | Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester |
EP2646453A1 (en) | 2010-11-30 | 2013-10-09 | Gilead Pharmasset LLC | Compounds |
WO2012088153A1 (en) * | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 |
JP2014513123A (ja) * | 2011-05-02 | 2014-05-29 | ギリアード サイエンシーズ, インコーポレイテッド | 無定形固体の塩 |
EA026587B1 (ru) | 2011-07-07 | 2017-04-28 | Янссен Сайенсиз Айрлэнд Юси | Лекарственная форма для перорального применения на основе даруновира и способ её получения |
MX336627B (es) | 2011-08-16 | 2016-01-26 | Gilead Sciences Inc | Hemifumarato de tenofovir alafenamida. |
RS56975B1 (sr) | 2011-09-16 | 2018-05-31 | Gilead Pharmasset Llc | Metode za lečenje hcv-a |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US9089574B2 (en) | 2011-11-30 | 2015-07-28 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
EP2802315A1 (en) | 2012-01-12 | 2014-11-19 | Gilead Sciences, Inc. | Pharmaceutical compositions and methods for their preparation |
AU2013214879A1 (en) | 2012-02-03 | 2014-08-07 | Gilead Sciences, Inc. | Methods and intermediates for preparing pharmaceutical agents |
WO2013130766A1 (en) | 2012-03-01 | 2013-09-06 | Gilead Sciences, Inc. | Spray dried formulations |
WO2014000178A1 (en) * | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
CN104540813A (zh) * | 2012-06-27 | 2015-04-22 | 默沙东公司 | 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法 |
CN103694196A (zh) * | 2012-09-27 | 2014-04-02 | 上海迪赛诺化学制药有限公司 | 细胞色素p450单加氧酶抑制剂中间体及其制法和用途 |
WO2014105777A1 (en) * | 2012-12-26 | 2014-07-03 | Assia Chemical Industries Ltd. | Cobicostat dichlohydrate salt |
PT2950786T (pt) | 2013-01-31 | 2020-03-03 | Gilead Pharmasset Llc | Formulação de combinação de dois compostos antivirais |
WO2014194519A1 (en) | 2013-06-07 | 2014-12-11 | Merck Sharp & Dohme Corp. | Imidazole derivatives and methods of use thereof for improving pharmacokinetics of drug |
CN104370777A (zh) * | 2013-08-13 | 2015-02-25 | 上海迪赛诺化学制药有限公司 | 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用 |
KR102239196B1 (ko) | 2013-08-27 | 2021-04-12 | 길리애드 파마셋 엘엘씨 | 2종의 항바이러스 화합물의 조합 제제 |
WO2015070366A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
WO2015070367A1 (en) | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Piperidine or piperazine linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
US20170035911A1 (en) | 2013-11-29 | 2017-02-09 | Mylan Laboratories Ltd. | Amorphous Cobicistat Solid Dispersion |
SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
CN105198829B (zh) * | 2015-08-15 | 2017-10-31 | 浙江永宁药业股份有限公司 | 一种可比司他中间体的制备方法及其中间体和用途 |
TW201728582A (zh) | 2016-01-28 | 2017-08-16 | 基利科學股份有限公司 | 結晶型 |
US10653681B2 (en) | 2016-03-16 | 2020-05-19 | Recurium Ip Holdings, Llc | Analgesic compounds |
CN105884760B (zh) * | 2016-06-13 | 2019-01-04 | 厦门市蔚嘉化学科技有限公司 | 一种可比司他中间体的制备方法 |
CN107674039A (zh) * | 2016-08-01 | 2018-02-09 | 上海朴颐化学科技有限公司 | 一种可比西他中间体的制备方法 |
AU2017305303B2 (en) * | 2016-08-04 | 2020-05-28 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
WO2018064071A1 (en) | 2016-09-27 | 2018-04-05 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
EP3558304A2 (en) | 2016-12-23 | 2019-10-30 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases |
ES2969496T3 (es) | 2017-08-01 | 2024-05-20 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2- il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
GB2590198B (en) | 2017-12-07 | 2022-02-23 | Univ Emory | N4-hydroxycytidine derivatives and anti-viral uses related thereto |
CN112771096B (zh) * | 2018-11-26 | 2023-06-13 | 三菱瓦斯化学株式会社 | 水系环氧树脂组合物和其固化物 |
CN111329858B (zh) * | 2018-12-18 | 2022-09-20 | 深圳先进技术研究院 | 一种小分子抑制剂在抑制病毒沉默抑制蛋白中的应用 |
CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司(Us) | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
CN116437958A (zh) | 2020-11-11 | 2023-07-14 | 吉利德科学公司 | 鉴定对采用gp120 CD4结合位点导向的抗体的疗法敏感的HIV患者的方法 |
TW202342448A (zh) | 2021-12-03 | 2023-11-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
AU2022403012A1 (en) | 2021-12-03 | 2024-06-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
TW202412779A (zh) | 2021-12-03 | 2024-04-01 | 美商基利科學股份有限公司 | 用於hiv病毒感染之治療性化合物 |
TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
TW202402280A (zh) | 2022-07-01 | 2024-01-16 | 美商基利科學股份有限公司 | 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物 |
US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
US20240226130A1 (en) | 2022-10-04 | 2024-07-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3354866A (en) * | 1966-04-25 | 1967-11-28 | Frank D Karkoska | Coating apparatus including means to rotate and translate a rod-substrate |
US3882114A (en) * | 1967-10-26 | 1975-05-06 | Oreal | N-(morpholinomethyl carbamyl) cysteamine and glycine |
GB1339764A (en) * | 1971-03-29 | 1973-12-05 | Ici Ltd | Pyridine derivatives |
US3957774A (en) * | 1972-04-17 | 1976-05-18 | L'oreal | N-morpholinomethyl-n-'-substituted ethyl and propylureas |
US5142056A (en) * | 1989-05-23 | 1992-08-25 | Abbott Laboratories | Retroviral protease inhibiting compounds |
HU186777B (en) | 1981-07-09 | 1985-09-30 | Magyar Tudomanyos Akademia | Process for producing complex-forming agents of crown-ether base and ionoselective membranelektrodes containing them |
DE3478684D1 (en) * | 1983-11-02 | 1989-07-20 | Magyar Tudomanyos Akademia | Crown ether derivatives |
US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5362912A (en) * | 1989-05-23 | 1994-11-08 | Abbott Laboratories | Process for the preparation of a substituted diaminodiol |
EP0428849A3 (en) | 1989-09-28 | 1991-07-31 | Hoechst Aktiengesellschaft | Retroviral protease inhibitors |
US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
IE913840A1 (en) | 1990-11-20 | 1992-05-20 | Abbott Lab | Retroviral protease inhibiting compounds |
JPH06127981A (ja) | 1992-03-03 | 1994-05-10 | Fuainiteii Kk | 複合複層ガラス及びそれを使用した窓 |
US5556418A (en) * | 1993-07-06 | 1996-09-17 | Pappas; Panagiotis T. | Method and apparatus for pulsed magnetic induction |
US5968942A (en) * | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
DK1302468T3 (da) | 1992-12-29 | 2009-03-02 | Abbott Lab | Fremgangsmåder og mellemprodukter til fremstilling af forbindelser, der inhiberer retroviral protease |
US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
UA49803C2 (uk) * | 1994-06-03 | 2002-10-15 | Дж.Д. Сьорль Енд Ко | Спосіб лікування ретровірусних інфекцій |
US5567823A (en) * | 1995-06-06 | 1996-10-22 | Abbott Laboratories | Process for the preparation of an HIV protease inhibiting compound |
US6037157A (en) * | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
US5763464A (en) * | 1995-11-22 | 1998-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same |
US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
AU2010299A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs os aspartyl protease inhibitors |
FR2773994B1 (fr) | 1998-01-23 | 2002-10-11 | Univ Nice Sophia Antipolis | Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central |
FR2779653B1 (fr) * | 1998-06-11 | 2002-12-20 | Inst Nat Sante Rech Med | Utilisation de composes modulateurs du proteasome en therapie |
EP1733725B2 (en) * | 1999-06-04 | 2012-08-08 | Abbott Laboratories | Pharmaceutical solution comprising ritonavir, a solvent (long chain fatty acid) and water |
RU2247123C2 (ru) | 1999-10-06 | 2005-02-27 | Тиботек Фармасьютикалз Лтд. | Гексагидрофуро [2,3-b] фуран-3-ил-n-{3-[(1,3-бензодиоксол-5- илсульфонил)(изобутил)амино]-1-бензил -2-гидроксипропил}карбамат, фармацевтическая композиция на их основе, способы ингибирования и способ лечения |
US6252336B1 (en) | 1999-11-08 | 2001-06-26 | Cts Corporation | Combined piezoelectric silent alarm/battery charger |
WO2001082919A2 (en) * | 2000-05-04 | 2001-11-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of and compounds for inhibiting calpains |
US6946449B2 (en) * | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
US7193065B2 (en) * | 2001-07-13 | 2007-03-20 | Roche Diagnostics Operations, Inc. | Protease inhibitor conjugates and antibodies useful in immunoassay |
US7285566B2 (en) | 2002-01-07 | 2007-10-23 | Erickson John W | Resistance-repellent retroviral protease inhibitors |
US7279487B2 (en) | 2002-01-17 | 2007-10-09 | Merck & Co., Inc. | Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors |
US7205413B2 (en) * | 2002-05-03 | 2007-04-17 | Transform Pharmaceuticals, Inc. | Solvates and polymorphs of ritonavir and methods of making and using the same |
AR042095A1 (es) | 2002-11-20 | 2005-06-08 | Japan Tobacco Inc | Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih |
JP2004184681A (ja) * | 2002-12-03 | 2004-07-02 | Konica Minolta Holdings Inc | 熱現像感光材料 |
JP2006515624A (ja) | 2003-01-14 | 2006-06-01 | ギリアード サイエンシーズ, インコーポレイテッド | 組み合わせ抗ウイルス療法のための組成物および方法 |
TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
US7737608B2 (en) | 2003-07-30 | 2010-06-15 | The Boeing Company | Enhanced amplitude piezoelectric motor apparatus and method |
JP2005091988A (ja) * | 2003-09-19 | 2005-04-07 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料及び画像形成方法 |
ES2319775T3 (es) * | 2003-10-27 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Combinaciones para el tratamiento del vhc. |
BRPI0401742B8 (pt) | 2004-05-13 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir |
MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
JP2006003701A (ja) * | 2004-06-18 | 2006-01-05 | Konica Minolta Medical & Graphic Inc | 熱現像感光材料および画像形成方法 |
WO2006014282A2 (en) * | 2004-07-06 | 2006-02-09 | Abbott Laboratories | Prodrugs of hiv protease inhibitors |
US7786153B2 (en) * | 2005-03-02 | 2010-08-31 | Abbott Laboratories Inc. | Compounds that are useful for improving pharmacokinetics |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
EP3696171A1 (en) | 2006-07-07 | 2020-08-19 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
EP2465855A1 (en) | 2006-08-31 | 2012-06-20 | Abbott Laboratories | Cytochrome P450 oxidase inhibitors and uses thereof |
HUE029866T2 (en) * | 2007-02-23 | 2017-03-28 | Gilead Sciences Inc | Modulation of pharmacokinetic parameters of therapeutic agents |
JP5547067B2 (ja) | 2007-06-29 | 2014-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | 治療組成物およびその使用 |
EA200971093A1 (ru) | 2007-06-29 | 2010-08-30 | Джилид Сайэнс, Инк. | Терапевтические композиции и их применение |
AR067412A1 (es) * | 2007-07-06 | 2009-10-07 | Gilead Sciences Inc | Moduladores de propiedades farmaceuticas de productos terapeuticos |
ES2428774T3 (es) | 2007-12-27 | 2013-11-11 | Baxter International Inc. | Procedimiento y composiciones para detectar específicamente moléculas poliméricas fisiológicamente aceptables |
US10039718B2 (en) | 2008-05-02 | 2018-08-07 | Gilead Sciences, Inc. | Use of solid carrier particles to improve the processability of a pharmaceutical agent |
EA021313B1 (ru) | 2009-02-06 | 2015-05-29 | Джилид Сайэнс, Инк. | Таблетки для комбинированной терапии |
-
2007
- 2007-07-06 EP EP20167933.9A patent/EP3696171A1/en active Pending
- 2007-07-06 RS RS20150590A patent/RS54237B9/sr unknown
- 2007-07-06 MX MX2009000234A patent/MX2009000234A/es active IP Right Grant
- 2007-07-06 JP JP2009518393A patent/JP4881433B2/ja active Active
- 2007-07-06 DK DK07836007.0T patent/DK2049506T4/da active
- 2007-07-06 PL PL07836007T patent/PL2049506T3/pl unknown
- 2007-07-06 EA EA200900155A patent/EA020489B1/ru active Protection Beyond IP Right Term
- 2007-07-06 ES ES12167594.6T patent/ES2611308T3/es active Active
- 2007-07-06 EP EP07836007.0A patent/EP2049506B2/en active Active
- 2007-07-06 US US12/306,198 patent/US8067449B2/en active Active
- 2007-07-06 EP EP12167594.6A patent/EP2487165B1/en active Active
- 2007-07-06 SI SI200731667T patent/SI2049506T1/sl unknown
- 2007-07-06 BR BRPI0714055A patent/BRPI0714055B8/pt active IP Right Grant
- 2007-07-06 TW TW096124727A patent/TWI411613B/zh active
- 2007-07-06 PT PT78360070T patent/PT2049506E/pt unknown
- 2007-07-06 SG SG2012050464A patent/SG183007A1/en unknown
- 2007-07-06 AR ARP070103029A patent/AR061838A1/es active IP Right Grant
- 2007-07-06 CA CA002653374A patent/CA2653374A1/en not_active Abandoned
- 2007-07-06 KR KR1020097002544A patent/KR101477822B1/ko active IP Right Grant
- 2007-07-06 PT PT121675946T patent/PT2487165T/pt unknown
- 2007-07-06 KR KR1020137033735A patent/KR20140004808A/ko not_active Application Discontinuation
- 2007-07-06 ES ES16180602T patent/ES2796275T3/es active Active
- 2007-07-06 ES ES07836007.0T patent/ES2546378T3/es active Active
- 2007-07-06 WO PCT/US2007/015604 patent/WO2008010921A2/en active Application Filing
- 2007-07-06 CN CN201310141408.6A patent/CN103275033B/zh active Active
- 2007-07-06 EA EA201270738A patent/EA025845B1/ru active Protection Beyond IP Right Term
- 2007-07-06 KR KR1020157008020A patent/KR101636221B1/ko active IP Right Grant
- 2007-07-06 HU HUE07836007A patent/HUE025565T4/en unknown
- 2007-07-06 US US11/825,605 patent/US7939553B2/en active Active
- 2007-07-06 TW TW102126891A patent/TWI496778B/zh active
- 2007-07-06 AP AP2008004720A patent/AP2985A/xx active
- 2007-07-06 ME MEP-2015-590A patent/ME02258B/me unknown
- 2007-07-06 EP EP16180602.1A patent/EP3112355B1/en active Active
- 2007-07-06 CN CN2007800256073A patent/CN101490023B/zh active Active
- 2007-07-06 AU AU2007275860A patent/AU2007275860C1/en active Active
- 2007-07-06 NZ NZ573060A patent/NZ573060A/en unknown
-
2008
- 2008-11-25 IL IL195488A patent/IL195488A/en active IP Right Grant
-
2009
- 2009-02-06 HR HRP20090077AA patent/HRP20090077B1/hr not_active IP Right Cessation
- 2009-02-06 NO NO20090593A patent/NO343776B1/no active Protection Beyond IP Right Term
- 2009-06-08 HK HK09105118.7A patent/HK1126485A1/xx active IP Right Maintenance
- 2009-06-08 HK HK17105753.7A patent/HK1232217A1/zh unknown
-
2011
- 2011-05-09 US US13/103,970 patent/US8383655B2/en active Active
- 2011-10-31 JP JP2011239688A patent/JP2012051933A/ja not_active Withdrawn
-
2013
- 2013-01-10 US US13/738,764 patent/US20130123311A1/en not_active Abandoned
- 2013-12-20 US US14/137,555 patent/US20140105859A1/en not_active Abandoned
-
2014
- 2014-04-29 IL IL232320A patent/IL232320A0/en unknown
- 2014-05-02 US US14/268,891 patent/US20150011775A1/en not_active Abandoned
-
2015
- 2015-01-20 US US14/601,132 patent/US9139541B2/en active Active
- 2015-07-08 HR HRP20150744TT patent/HRP20150744T2/hr unknown
- 2015-08-17 US US14/828,406 patent/US20160067360A1/en not_active Abandoned
- 2015-09-14 CY CY20151100800T patent/CY1116688T1/el unknown
- 2015-11-06 FI FIEP07836007.0T patent/FI2049506T4/fi active
- 2015-11-06 LU LU92864C patent/LU92864I2/xx unknown
- 2015-11-11 LT LTPA2015040C patent/LTC2049506I2/lt unknown
- 2015-11-26 CY CY2015046C patent/CY2015046I1/el unknown
- 2015-12-02 FR FR15C0078C patent/FR15C0078I2/fr active Active
- 2015-12-08 NL NL300780C patent/NL300780I2/nl unknown
-
2016
- 2016-03-17 US US15/073,367 patent/US20160303088A1/en not_active Abandoned
- 2016-11-01 US US15/340,466 patent/US20170143680A1/en not_active Abandoned
-
2017
- 2017-12-05 US US15/831,703 patent/US20180221348A1/en not_active Abandoned
-
2019
- 2019-04-23 NO NO20190528A patent/NO345343B1/no unknown
- 2019-07-04 NO NO2019027C patent/NO2019027I1/no unknown
- 2019-07-19 NO NO2019031C patent/NO2019031I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR15C0078I2 (fr) | Modulateurs de proprietes pharmacocinetiques d'agents therapeutiques | |
FR20C1021I1 (fr) | Modulateurs de propriétés pharmacocinétiques d'agents thérapeutiques | |
ZA200810234B (en) | Benzimidazole modulators of vr1 | |
EP2068864A4 (en) | THERAPEUTIC USES OF UROLITHINS | |
BRPI0716365A2 (pt) | "artigo odontolàgico" | |
ZA200901842B (en) | Ocular devices and methods of making and using thereof | |
FR2898940B1 (fr) | Corps central de tuyere de turboreacteur | |
FR2899087B1 (fr) | Protection pour endoscope et endoscope correspondant | |
FR2898636B1 (fr) | Structure de queue-d'aronde de soufflante. | |
EP2069380A4 (en) | RNAI MODULATION OF SCAP AND ITS THERAPEUTIC USE | |
GB0506835D0 (en) | Therapeutic use of nefopam | |
BRPI0716742A2 (pt) | Lactamas terapêuticas | |
BRPI0716374A2 (pt) | "dispositivos médicos" | |
FR2915325B1 (fr) | Structure d'engagement de connecteurs | |
BRPI0714318A2 (pt) | Utilização de 2-benzoil-imidazopiridinas em terapêutica | |
FR2905259B1 (fr) | Prothese de cheville | |
GB0515703D0 (en) | Therapeutic use of nefopam | |
FR2895710B1 (fr) | Monopode d'arrimage pour brancard | |
HUP0600042A3 (en) | New medical use of thiolated pyrimidine-mononucleotides and -nucleosides | |
ES1064542Y (es) | "airbag fijo de guardarrail" | |
TH97396B (th) | ตัวควบคุมสัมบัติทางเภสัชจลนศาสตร์ของสารในการรักษา | |
FR2903313B1 (fr) | Capuchon d'aiguille | |
UA13364S (uk) | Жакет жіночий | |
ES1062356Y (es) | "aparato multimedia universal emisor y reproductor de imagen y sonido" | |
FR2897531B1 (fr) | Moyen de traitement de l'enuresie dite "primaire" |